USSTOCK.TODAY
Pre-Market
Log in Sign up

Evaxion Announces 3-Year Phase 2 Clinical Trial Results for Personalized Melanoma Vaccine

Stocktwits +1 ·

EVAX
EVAX Evaxion A/S ADR
$3.71 0.00%
View chart & analysis →
  1. 1Evaxion reported promising 3-year results from its Phase 2 clinical trial of a personalized vaccine for advanced melanoma.
  2. 2Evaxion vaccine targets recorded an 89% rate of activating specific T-cell responses.
  3. 3EVAX shares rose more than 8% in pre-market trading on Friday.

So what's the key point?

Evaxion received positive results from testing its cancer treatment vaccine. The stock price rose because 89% of people who received the vaccine showed a response.

Source Stocktwits +1 · View original ↗

Related 3-line summaries

Bond market issues warning over capital expenditure for AI infrastructure construction The Motley Fool +1 · 58m agoBooz Allen Hamilton Holding Corp. Beats Second Quarter Earnings Estimates Associated Press +3 · 1h agoKraft Heinz Earnings Decline and Changes in Management Strategy The Motley Fool +1 · 1h ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news